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Key messages
What is already known about this subject?
 ► Occupational respiratory exposures have been 
shown to be an important cause of chronic 
work- related respiratory disease at national and 
global level.
 ► The last analysis of this issue at the global level 
was for the year 2000—this paper provides a 
new analysis for 2016.
What are the new findings?
 ► Analysis of the Global Burden of Disease data 
set suggests that globally there were about 
519,100 deaths and 13.6 million disability- 
adjusted life years in 2016 from chronic 
respiratory disease due to occupational airborne 
exposures.
 ► The population attributable fraction for chronic 
obstructive pulmonary disease (COPD) was 17% 
and for asthma was 10%.
 ► Workplace exposures resulting in COPD, 
asthma and pneumoconioses remain important 
contributors to the burden of disease in all 
regions of the world.
How might this impact on policy or clinical 
practice in the foreseeable future?
 ► These findings highlight opportunities to 
continue to reduce chronic respiratory disease 
burden worldwide by improving prevention and 
control of workplace airborne exposures.
AbsTrACT
Objectives This paper presents detailed analysis of 
the global and regional burden of chronic respiratory 
disease arising from occupational airborne exposures, as 
estimated in the global Burden of Disease 2016 study.
Methods The burden of chronic obstructive pulmonary 
disease (cOPD) due to occupational exposure to 
particulate matter, gases and fumes, and secondhand 
smoke, and the burden of asthma resulting from 
occupational exposure to asthmagens, was estimated 
using the population attributable fraction (PaF), 
calculated using exposure prevalence and relative risks 
from the literature. PaFs were applied to the number 
of deaths and disability- adjusted life years (DalYs) for 
cOPD and asthma. Pneumoconioses were estimated 
directly from cause of death data. age- standardised rates 
were based only on persons aged 15 years and above.
results The estimated PaFs (based on DalYs) were 
17% (95% uncertainty interval (Ui) 14%–20%) for 
cOPD and 10% (95% Ui 9%–11%) for asthma. There 
were estimated to be 519 000 (95% Ui 441,000–
609,000) deaths from chronic respiratory disease in 
2016 due to occupational airborne risk factors (cOPD: 
460,100 [95% Ui 382,000–551,000]; asthma: 37,600 
[95% Ui 28,400–47,900]; pneumoconioses: 21,500 
[95% Ui 17,900–25,400]. The equivalent overall burden 
estimate was 13.6 million (95% Ui 11.9–15.5 million); 
DalYs (cOPD: 10.7 [95% Ui 9.0–12.5] million; asthma: 
2.3 [95% Ui 1.9–2.9] million; pneumoconioses: 0.58 
[95% Ui 0.46–0.67] million). rates were highest in 
males; older persons and mainly in Oceania, asia and 
sub- saharan africa; and decreased from 1990 to 2016.
Conclusions Workplace exposures resulting in cOPD, 
asthma and pneumoconiosis continue to be important 
contributors to the burden of disease in all regions of 
the world. This should be reducible through improved 
prevention and control of relevant exposures.
InTrOduCTIOn
Airborne respiratory hazards (inorganic and organic 
particulate matter, vapours, gases and fumes) are 
a common exposure in occupational settings and 
many studies have identified resulting malignant 
and chronic respiratory disease as an important 
component of the occupational injury and disease 
burden at both country and global levels.1–10 Work- 
related respiratory diseases remain a problem even 
in high- income countries, as shown by incident 
cases of pneumoconioses that are still occurring.11 12
The Global Burden of Disease (GBD) Compar-
ative Risk Assessment (CRA) project was the first 
to consider the burden of occupational chronic 
respiratory disease comprehensively at a regional 
and global level, estimating the burden for the year 
2000.13 That study included airborne exposures 
leading to asthma, chronic obstructive pulmonary 
disease (COPD), asbestosis, coal workers’ pneumo-
coniosis (CWP) and silicosis.14
The new GBD initiative, conducted by the Insti-
tute of Health Metrics and Evaluation, first focused 
on 201015 and has been updated several times 
since.16–19 It provides a detailed analysis of the 
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burden of disease and injury overall and arising from specific 
risk factors. One set of those risk factors comprises occupational 
exposures,18but no detailed analysis of the occupational risk 
factor results has been undertaken.
This paper presents a detailed analysis of the global and 
regional burden of chronic respiratory disease arising from non- 
infectious occupational airborne exposures, as estimated in the 
GBD 2016 study. Malignant occupational respiratory disease20 
and an overview of all occupational risk factors21 are considered 
in companion papers.20
MeTHOds
General approach
The general methodology used in GBD 2016 is described else-
where,18 as is the overall approach to occupational risk factors.21 
These methods are briefly summarised here. A more detailed 
description is provided here of the analyses of occupational 
exposures to particulate matter, gases and fumes (PMGF), 
secondhand smoke (SHS), asthmagens and pneumoconiotic 
dusts and their associated outcomes.
The burden of occupational respiratory disease for PMGF and 
SHS (causing COPD) and for asthmagens was estimated using 
the population attributable fraction (PAF), that is, the propor-
tion of deaths or disability- adjusted life years (DALYs) that would 
not have occurred if exposure was at the theoretical minimum 
risk exposure level; this was then used to estimate attribut-
able numbers of deaths or DALYs. The PAF requires informa-
tion on the relative risk of the disease due to the exposure of 
interest and the proportion of the target population exposed. 
Pneumoconioses were estimated directly as part of the overall 
GBD estimates of prevalence and deaths for each included 
cause. Age- standardised rates (per 100 000 people) were based 
only on persons aged 15 and above. Results were calculated 
for all years from 1990 to 2016, inclusive; the 2016 findings 
are the focus of this paper. The socio- demographic index (SDI) 
is a composite indicator of development status based on total 
fertility rate, mean education for those aged 15 and older and lag 
distributed income per capita.18Region- specific, SDI- specific and 
global results are reported here. Country- specific information is 
available through the GBD Compare data visualisation.22 High- 
income countries were defined as countries in the Australasia, 
high- income North America, Western Europe and Asia Pacific 
regions, and low/middle- income (LMI) countries as all other 
countries. Employment data came from the International Labour 
Organization Labour Force,23 supplemented where necessary by 
sub- national data sources and modelling. PAFs for all carcino-
gens except asbestos were estimated for each age- sex- country 
group using the equation based on Levin24:
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where P(x) is the proportion of persons exposed at level x 
in the relevant population and RR(x) is the relative risk corre-
sponding to exposure level x.
PMGF and sHs
Industry was used as a proxy for exposure to PMGF because 
we identified no suitable and valid data sources at a country or 
global level of exposure to PMGF, either singly or to PMGF 
as a group. Current industry was used as the basis of expo-
sure estimates, but the estimates of proportions exposed (ie, 
workers who experienced more than trivial exposure) within 
each industry (nine categories—see online supplementary 
table S1) were designed to take into account past exposure 
(to estimate ever exposed), given that both past and current 
exposure appear to increase the risk of COPD. Estimates of 
proportion exposed at lower and higher levels in high income 
and LMI countries were based on sparse published data (see 
online supplementary material) and expert opinion by GBD 
collaborators (online supplementary table S1). Information on 
risk was obtained by conducting a systematic review of inter-
national literature and meta- analysis (unpublished) of relevant 
results.5 25 Relative risks in these studies were for COPD greater 
than or equal toGlobal Initiative for Chronic Obstructive Lung 
Disease(GOLD) stage II: defined as requiring non- reversibility 
after using bronchodilators for provocation, a forced expi-
ratory volume in one second/forced vital capacity (FEV1/
FVC) ratio of less than 0.70 and an FEV1 of less than 80% 
predicted.26 Relative risk estimates were used for an overall 
‘lower’ level (RR=1.44; 95% CI 1.07–1.95) and an overall 
‘higher’ level (RR=2.31; 95% CI 1.45 to 3.73) of exposure to 
the agents of concern (‘higher’ and ‘lower’ were based on the 
exposure descriptions in the papers).5 25 The reference group 
was persons not working and persons working in trade, finance 
or service industries. The prevalence of exposure to PMGF was 
determined using the following equation:
 
1) Prevalence of Exposurec,y,s,a,l =
∑
EA
ProportionEAC,y ∗ EAPc,y,s,
∗Exposure level proportionEAl 
where EAP = economically active population, c = country, s 
= sex, EA = economic activity, l = level of exposure, y =year 
and a = age.
Exposure information on SHS was based on the CAREX 
(Carcinogen Exposure) database, which provides industry- 
specific information from 1990 to 1993 on the prevalence 
of exposure to various carcinogens in countries of Western 
Europe,27 as described elsewhere.20 The relevant relative risks 
were those used for SHS in the general GBD 2016 analysis.18
Asthmagens
Exposure and relative risks for asthmagens were based on the 
current occupation distribution (eight categories—see online 
supplementary table S2) because there were no suitable and valid 
data sources at a country or global level describing exposure to 
the wide range of occupational asthmagens. All relative risk 
information, except that for agricultural occupations, came from 
a study by Karjalainen and coworkers, a comprehensive national 
population study of incident asthma.7 8 Relative risks for agri-
cultural occupations were based on a study by Kogevinas and 
coworkers,28 using a weighted average of the separate estimates 
for ‘farmers’ and ‘agricultural’ workers provided in the paper. 
This information was used because the results were thought to 
be more generalisable to agriculture in the rest of the world, 
especially for LMI regions. Separate risks were available and 
used for males and females (except for agricultural operations), 
although the sex- specific risks were similar and within the limits 
of random variation. The same relative risks were used for all 
age groups. The counterfactual was persons not working and 
administrative workers. Byssinosis was included as asthma for 
the purposes of the analysis. The prevalence of exposure to asth-
magens was determined using the following equation:
 
2) Prevalence of Exposurec,y,s,a =
∑
EA
Proportionoccc,y ∗ EAPc,y,s, 
where EAP = economically active population, c = country, s 
= sex, OCC = occupation, y = year and a = age.
 o
n
 April 21, 2020 by guest. Protected by copyright.
http://oem
.bmj.com/
O
ccup Environ M
ed: first published as 10.1136/oem
ed-2019-106013 on 13 February 2020. Downloaded from
 
144 GBD 2016 Occupational Chronic Respiratory Risk Factors Collaborators.Occup Environ Med 2020;77:142–150. doi:10.1136/oemed-2019-106013
Workplace
Ta
bl
e 
1 
G
lo
ba
l o
cc
up
at
io
na
l- a
tt
rib
ut
ab
le
 d
ea
th
s, 
DA
LY
s 
an
d 
PA
Fs
 fr
om
 c
hr
on
ic
 re
sp
ira
to
ry
 d
is
ea
se
 d
ue
 to
 a
irb
or
ne
 e
xp
os
ur
es
 b
y 
ris
k 
fa
ct
or
 a
nd
 s
ex
, 2
01
6 
(n
um
be
r, 
pe
rc
en
t a
nd
 p
ro
po
rt
io
n 
[9
5%
 
un
ce
rt
ai
nt
y 
in
te
rv
al
])*
ri
sk
 fa
ct
or
To
ta
l
d
ea
th
s
M
al
es
‡
%
§
M
al
es
dA
LY
s
To
ta
l
%
¶
M
al
es
PA
Fs
†
To
ta
l
Fe
m
al
es
Fe
m
al
es
Fe
m
al
es
As
th
m
ag
en
s
26
 1
03
11
 4
71
37
 5
74
7.
2
1 
46
8 
34
7
87
1 
13
3
2 
33
9 
48
0
17
.2
13
.0
7.
1
9.
9
(1
7 
90
0–
35
 3
00
)
(8
70
0–
15
 2
00
)
(2
8 
40
0–
47
 9
00
)
 
 
(1
 1
41
 2
00
–1
 8
74
 3
00
)
(6
66
 1
00
–1
 1
09
 6
00
)
(1
 8
60
 9
00
–2
 9
23
 3
00
)
 
 
(1
2.
0–
14
.0
)
(6
.3
–8
.0
)
(9
.0
–1
1.
0)
PM
G
F+
SH
S*
*
34
3 
12
2
11
6 
95
8
46
0 
08
0
88
.6
7 
96
9 
98
6
2 
71
7 
96
7
10
 6
87
 9
53
78
.6
21
.0
11
.0
17
.0
(2
70
 9
00
–4
22
 0
00
)
(8
7 
10
0–
15
3 
30
0)
(3
81
 5
00
–5
51
 3
00
)
 
 
(6
 5
18
 0
00
–9
 4
69
 2
00
)
(2
 1
43
 4
00
–3
 3
28
 6
00
)
(9
 0
19
 9
00
–1
2 
51
7 
00
0)
 
 
(1
8.
0–
25
.0
)
(9
.0
–1
3.
0)
(1
4.
0–
20
.0
)
Pn
eu
m
oc
on
io
tic
 d
us
ts
18
 9
97
24
91
21
 4
88
4.
1
51
8 
91
7
58
 0
60
57
6 
97
7
4.
2
10
0
10
0
10
0
(1
5 
50
0–
22
 7
00
)
(2
10
0–
32
00
)
(1
7 
90
0–
25
 4
00
)
 
 
(4
39
 9
00
–6
11
 3
00
)
(4
9 
40
0–
70
 7
00
)
(4
93
 6
00
–6
73
 5
00
)
 
 
 
 
 
 
 
 
To
ta
l
38
8 
22
2
13
0 
92
0
51
9 
14
2
10
0.
0
9 
95
7 
26
9
3 
64
7 
17
0
13
 6
04
 4
38
10
0.
0
19
.0
9.
0
15
.0
(3
13
 9
00
–4
66
 6
00
)
(1
00
 5
00
–1
67
 7
00
)
(4
41
 0
00
–6
08
 9
00
)
 
 
(8
 5
20
 2
00
–1
1 
45
0 
30
0)
(3
 0
10
 8
00
–4
 3
35
 2
00
)
(1
1 
91
2 
00
0–
15
 5
02
 8
00
)
 
 
(1
6.
0–
22
.0
)
(7
.0
–1
1.
0)
(1
3.
0–
17
.0
)
*D
AL
Ys
=
di
sa
bi
lit
y-
 ad
ju
st
ed
 li
fe
 y
ea
rs
; P
AF
=
po
pu
la
tio
n 
at
tr
ib
ut
ab
le
 fr
ac
tio
n.
†P
AF
s 
(%
) b
as
ed
 o
n 
DA
LY
s.
‡T
he
 n
um
be
rs
 in
 b
ra
ck
et
s 
in
 th
e 
w
ho
le
 ta
bl
e 
ar
e 
95
%
 u
nc
er
ta
in
ty
 in
te
rv
al
s.
§P
er
ce
nt
ag
e 
of
 c
hr
on
ic
 re
sp
ira
to
ry
 d
is
ea
se
 d
ea
th
s 
du
e 
to
 o
cc
up
at
io
na
l r
is
k 
fa
ct
or
s 
th
at
 w
er
e 
du
e 
to
 th
is
 ri
sk
 fa
ct
or
.
¶P
er
ce
nt
ag
e 
of
 c
hr
on
ic
 re
sp
ira
to
ry
 d
is
ea
se
 D
AL
Ys
 d
ue
 to
 o
cc
up
at
io
na
l r
is
k 
fa
ct
or
s 
th
at
 w
er
e 
du
e 
to
 th
is
 ri
sk
 fa
ct
or
.
**
Pa
rt
ic
ul
at
e 
m
at
te
r, 
ga
se
s 
an
d 
fu
m
es
 (P
M
G
F)
 a
nd
 s
ec
on
dh
an
d 
sm
ok
e 
(S
HS
) c
au
si
ng
 c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e.
Pneumoconiotic dusts
As mentioned, pneumoconioses were estimated directly as 
part of the overall GBD estimates of prevalence and deaths for 
each included cause, rather than using the attributable fraction 
approach. The methods used are described elsewhere.29 The 
attributable fraction is essentially 100% because virtually all 
pneumoconioses arise as a result of occupational exposure. Sepa-
rate estimates were available for silicosis, asbestosis and CWP, 
with the remaining cases grouped under an ‘other pneumoconi-
osis’ category.23
statistical approach
The main modelling and analyses employed to produce the 
GBD 2016 data, and the calculation and use of 95% uncertainty 
intervals (95% UI), were as described elsewhere.18 21 Uncertainty 
intervals are primarily presented in detail in the tables to assist 
with the flow of the text.
resuLTs
There were estimated to be about 519 000 (95% UI 
441 000–609 000) deaths from chronic respiratory disease 
in 2016 due to occupational airborne risk factors. The vast 
majority (460 000 [95% UI 382 000–551 000]; 89%) of these 
were due to COPD arising from PMGF and SHS. The remaining 
deaths were from asthma (37 600 [95% UI 28 400–47 900]; 7%), 
due to exposure to a range of asthmagens, and from pneumo-
coniosis (21 500 [95% UI 17 900–25 400]; 4%), arising from 
exposure to pneumoconiotic dusts. Males accounted for 75% 
(390 000) of the deaths overall and between 69% (asthmagens) 
and 88% (pneumoconiotic dusts) for individual risk factors. The 
relative contribution of the different risk factors was similar 
when the burden was measured in terms of DALYs (13.6 [95% 
UI 11.9–15.5] million DALYs overall; COPD: 10.7 [95% UI 
9.0–12.5] million; asthma: 2.3 [95% UI 1.9–2.9] million; pneu-
moconioses: 0.58 [95% UI 0.49–0.67] million), with 79% of the 
DALYs due to PMGF and SHS. Males accounted for 73% (9.9 
million) of the DALYs (table 1).
PMGF and sHs
The PAF for COPD arising from occupational exposures was 
17% (95% UI 14%–20%) for DALYs (16% for deaths), ranging 
from a low of 10% in Central sub- Saharan Africa to 21% in 
East Asia (table 2). The PAF was much higher in males (21%) 
than females (11%) and peaked at about 24% in 60–64- year- old 
males. The highest number of deaths and the highest rate of 
deaths from COPD due to occupational exposures occurred in 
the older age groups, often beyond usual retirement age. Males 
had three to four times the number and rate of deaths compared 
with females. The peak for number of DALYs occurred in the 
65–74 year age group, but the rate of DALYs increased consider-
ably with age and was highest in the 75–84 year group for both 
males and females (online supplementary figures S1- S4).
By far the highest number of deaths and DALYs from COPD 
occurred in East Asia and South Asia, the regions with the largest 
populations, which together accounted for about 71% of both 
measures. The highest rates of deaths were in Oceania, South 
Asia and East Asia, the rates in these three regions being consid-
erably higher than elsewhere (the lowest rates were in high- 
income Asia Pacific and Eastern Europe).
The same regions had the highest DALY rates (the lowest DALY 
rates were in Andean Latin America, high- income Asia Pacific and 
the Caribbean). Rates tended to be higher in low- middle and middle 
SDI regions, and there was considerable variation between regions. 
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Table 2 Deaths, YLLs, YLDs, DALYs and PAFs from COPD due to occupational exposure to PMGF and SHS, by region, 2016 (number, percent, rate, 
proportion)*
region
deaths deaths YLLs YLds dALYs dALYs deaths YLLs YLds dALYs YLL YLd PAF PAF
number % number number number % rate† rate† rate† rate† %‡ %‡ (deaths)§ (dALYs)¶
High- income North America 16 669 3.6 287 084 154 716 441 800 4.1 9.8 173 95 267 65.0 35.0 9.4 11.9
Australasia 1047 0.2 15 975 4922 20 897 0.2 7.7 122 39 161 76.4 23.6 10.0 13.1
High- income Asia Pacific 5150 1.1 61 981 70 847 132 828 1.2 4.8 61 76 136 46.7 53.3 12.0 15.5
Western Europe 18 258 4.0 250 656 73 485 324 141 3.0 7.8 113 35 148 77.3 22.7 9.1 11.6
Southern Latin America 2844 0.6 44 526 4967 49 493 0.5 10.8 174 20 194 90.0 10.0 12.2 14.3
Eastern Europe 6391 1.4 119 566 21 018 140 584 1.3 6.3 119 21 140 85.0 15.0 12.7 13.6
Central Europe 4622 1.0 78 183 20 299 98 482 0.9 7.9 136 36 172 79.4 20.6 12.2 13.9
Central Asia 2584 0.6 51 612 8277 59 889 0.6 10.1 190 29 219 86.2 13.8 16.4 16.8
Central Latin America 7042 1.5 107 850 25 554 133 404 1.2 9.3 139 31 171 80.8 19.2 13.6 15.1
Andean Latin America 1241 0.3 17 903 4217 22 120 0.2 7.1 99 23 122 80.9 19.1 15.3 16.1
Caribbean 1191 0.3 20 636 3576 24 213 0.2 7.2 126 22 147 85.2 14.8 13.2 14.2
Tropical Latin America 9936 2.2 179 699 25 150 204 849 1.9 13.7 239 32 271 87.7 12.3 15.1 17.3
East Asia 171 300 37.2 2 634 163 592 605 3 226 768 30.2 31.5 461 99 560 81.6 18.4 18.8 20.5
Southeast Asia 28 029 6.1 508 878 350 306 859 183 8.0 15.0 252 164 415 59.2 40.8 18.3 18.7
Oceania 886 0.2 21 518 3182 24 700 0.2 35.9 767 107 874 87.1 12.9 13.9 13.1
North Africa and Middle East 9834 2.1 193 777 69 764 263 541 2.5 6.9 125 42 167 73.5 26.5 12.4 12.8
South Asia 157 117 34.1 3 049 410 1 176 092 4 225 502 39.5 34.8 626 227 853 72.2 27.8 15.9 16.5
Southern sub- Saharan Africa 2117 0.5 39 719 15 450 55 169 0.5 11.2 197 72 269 72.0 28.0 12.7 12.3
Western sub- Saharan Africa 4775 1.0 105 149 39 099 144 248 1.3 7.9 144 49 192 72.9 27.1 16.2 15.6
Eastern sub- Saharan Africa 7716 1.7 154 524 46 238 200 761 1.9 12.3 217 60 277 77.0 23.0 19.4 18.3
Central sub- Saharan Africa 1333 0.3 27 051 8328 35 379 0.3 7.3 130 36 166 76.5 23.5 9.8 9.5
High SDI 41 455 9.0 630 080 319 949 950 029 8.9 7.7 122 65 187 66.3 33.7 9.8 12.4
High- middle SDI 55 985 12.2 855 050 280 400 1 135 450 10.6 12.6 191 63 253 75.3 24.7 15.7 17.4
Middle SDI 185 785 40.4 3 067 814 1 016 253 4 084 066 38.2 24.0 377 110 486 75.1 24.9 17.9 19.3
Low- middle SDI 156 339 34.0 2 995 849 971 878 3 967 727 37.1 29.5 522 169 691 75.5 24.5 15.9 16.2
Low SDI 20 517 4.5 421 068 129 612 550 681 5.2 16.2 291 83 374 76.5 23.5 15.2 14.9
Global 460 080 100.0 7 969 861 2 718 092 10 687 953 100.0 18.1 309 103 412 74.6 25.4 15.7 16.8
*YLL=years of life lost; YLD=years of life lived with disability; DALYs=disability- adjusted life years; PAF=population attributable fraction; COPD=chronic obstructive pulmonary disease; 
PMGF=particulate matter, gases and fumes; SHS=secondhand smoke.
†Per 100 000 persons.
‡Percentage of DALYs.
§Percentage of all COPD deaths due to occupational exposures.
¶Percentage of all COPD DALYs due to occupational exposures.
SDI, socio- demographic index.
Seventy- five percent of the DALYs were due to years of life lost 
(YLLs); this predominance of YLLs was seen in nearly all regions 
(table 2). Information on the separate contribution of SHS to COPD 
is presented in the online supplementary material.
Asthmagens
The PAF for asthma from occupational exposures was estimated 
to be 9.9% (95% UI 9.0%–10.9%) based on DALYs (8.9% [95% 
UI 7.8–10.1%] based on deaths), ranging from 4.1% in Central 
sub- Saharan Africa to 12.0% in South Asia (table 3). The PAF 
was higher for males (13%) than females (7%) and peaked at 
around 18% between the ages of about 35 and 49 years.
Deaths arising from occupational exposure to asthmagens 
occurred at all ages from 15 to 79 years, but the highest numbers 
occurred in persons aged 55–64 and the highest rates in persons 
aged 65–79. The burden was spread more evenly across age 
groups in terms of DALYs, with the highest number of DALYs in 
the 45–54 year age group and the highest rates in the 55–64 year 
age group (online supplementary figures S5- S8).
The highest number of deaths occurred in South Asia and 
Southeast Asia, and rates were highest in the low and low- middle 
SDI regions, particularly Oceania, South Asia and Southeast Asia 
(the lowest rates were in Western Europe and Central Europe). 
A similar pattern was seen for DALYs (the lowest rates were in 
East Asia and Tropical Latin America). Overall, YLLs and years 
of life with disability each contributed about 50% to the DALYs. 
However, low and low- middle SDI regions had a much higher 
proportion of DALYs due to YLLs compared with high- income 
regions, reflecting that a higher proportion of deaths occurred at 
younger ages in these regions compared with the high and high- 
middle SDI regions (table 3).
PneuMOCOnIOTIC dusTs
The PAF for all pneumoconioses was assumed to be 100%. Sili-
cosis (48%) was the largest specific cause of death from pneumo-
coniosis, ahead of asbestosis (16%) and CWP (12%), but about 
one- quarter of the deaths were classified in the ‘other pneu-
moconiosis’ category. There was a similar distribution between 
pneumoconiosis categories in terms of DALYs (table 4). The 
number of deaths increased with age until age 85 years and over, 
and the age- standardised death rates were highest in the older 
age groups. There was a broader distribution of DALYs across 
age groups, and although the rates still increased with increasing 
age, the rate was highest in the 75–84 year age group (online 
supplementary figures S9- S12).
The highest number of deaths and DALYs overall and for sili-
cosis and CWP occurred in East Asia, South Asia and Western 
Europe, with high- income North America replacing East Asia for 
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Table 3 Deaths, YLLs, YLDs, DALYs and PAFs from asthma due to occupational exposure to asthmagens, by region, 2016 (number, percent, rate, 
proportion)*
region
deaths deaths YLLs YLds dALYs dALYs deaths YLLs YLds dALYs YLL YLd PAF PAF
number % number number number % rate† rate† rate† rate† %‡ %‡ (deaths)§ (dALYs)¶
High- income North America 388 1.0 15 269 71 605 86 873 3.7 0.3 10.6 50.2 60.7 17.6 82.4 8.8 10.7
Australasia 23 0.1 857 11 291 12 148 0.5 0.2 7.4 100.1 107.5 7.1 92.9 4.3 9.0
High- income Asia Pacific 135 0.4 3493 34 431 37 923 1.6 0.2 4.2 46.3 50.5 9.2 90.8 2.6 8.0
Western Europe 182 0.5 6525 94 309 100 834 4.3 0.1 3.6 55.8 59.4 6.5 93.5 2.8 8.4
Southern Latin America 46 0.1 1558 12 849 14 407 0.6 0.2 6.2 51.6 57.8 10.8 89.2 4.9 7.5
Eastern Europe 204 0.5 6750 34 060 40 810 1.7 0.2 7.2 38.1 45.2 16.5 83.5 5.2 8.2
Central Europe 59 0.2 1877 16 773 18 650 0.8 0.1 3.6 34.7 38.3 10.1 89.9 3.4 8.2
Central Asia 166 0.4 5423 13 953 19 376 0.8 0.6 17.5 42.9 60.4 28.0 72.0 8.0 9.4
Central Latin America 185 0.5 6315 32 529 38 844 1.7 0.2 7.0 34.3 41.4 16.3 83.7 5.7 6.8
Andean Latin America 31 0.1 952 8977 9929 0.4 0.2 4.8 42.0 46.7 9.6 90.4 7.4 6.8
Caribbean 140 0.4 5049 8442 13 491 0.6 0.8 29.6 49.3 78.9 37.4 62.6 7.5 6.5
Tropical Latin America 176 0.5 6291 22 647 28 937 1.2 0.2 7.5 26.7 34.2 21.7 78.3 6.3 7.2
East Asia 1164 3.1 35 597 162 558 198 156 8.5 0.2 5.7 26.6 32.3 18.0 82.0 5.1 9.3
Southeast Asia 7315 19.5 224 974 142 208 367 182 15.7 3.3 96.0 57.8 153.8 61.3 38.7 9.5 11.0
Oceania 292 0.8 9862 2619 12 481 0.5 9.3 297.6 71.8 369.5 79.0 21.0 7.6 8.5
North Africa and Middle East 1344 3.6 47 971 84 044 132 015 5.6 0.7 25.3 41.3 66.6 36.3 63.7 6.0 6.7
South Asia 21 085 56.1 669 102 223 370 892 472 38.1 3.9 117.5 37.9 155.4 75.0 25.0 9.7 12.0
Southern sub- Saharan Africa 474 1.3 17 146 13 274 30 420 1.3 2.0 69.4 49.5 118.9 56.4 43.6 7.7 8.0
Western sub- Saharan Africa 1395 3.7 50 249 51 856 102 105 4.4 1.5 50.7 45.3 96.1 49.2 50.8 10.7 8.5
Eastern sub- Saharan Africa 2452 6.5 85 585 75 354 160 939 6.9 2.9 91.8 68.2 160.0 53.2 46.8 13.2 10.7
Central sub- Saharan Africa 316 0.8 11 315 10 173 21 487 0.9 1.2 41.1 33.1 74.1 52.7 47.3 5.1 4.1
High SDI 776 2.1 27 685 213 996 241 681 10.3 0.2 6.5 52.1 58.6 11.5 88.5 4.6 9.2
High- middle SDI 1320 3.5 44 449 185 336 229 785 9.8 0.3 9.1 38.1 47.2 19.3 80.7 6.2 9.1
Middle SDI 8807 23.4 277 589 316 569 594 158 25.4 1.0 30.5 34.5 65.0 46.7 53.3 8.1 9.3
Low- middle SDI 21 524 57.3 683 953 297 559 981 512 42.0 3.3 101.3 41.4 142.7 69.7 30.3 9.7 11.1
Low SDI 5147 13.7 178 483 113 860 292 343 12.5 2.9 94.3 52.3 146.5 61.1 38.9 9.9 8.9
Global 37 574 100.0 1 212 160 1 127 320 2 339 480 100.0 1.4 44.0 40.5 84.5 51.8 48.2 8.9 9.9
*YLL=years of life lost; YLD=years of life lived with disability; DALYs=disability- adjusted life years; PAF=population attributable fraction.
†Per 100 000 persons.
‡Percentage of DALYs.
§Percentage of all asthma deaths due to occupational exposures.
¶Percentage of all asthma DALYs due to occupational exposures.
SDI, socio- demographic index.
asbestosis deaths. The age- standardised death rates were highest 
in high- income Asia Pacific, East Asia and Oceania (the lowest 
rates were in Southeast Asia and the Caribbean), and the DALY 
rates highest in East Asia, Oceania and Southern sub- Saharan 
Africa (the lowest rates were in the Caribbean and Southeast 
Asia). Sixty- two percent of the silicosis deaths and 36% of the 
CWP deaths occurred in East Asia, and 27% of the asbestosis 
deaths occurred in Western Europe, which also had the second- 
highest rate (behind East Asia) of silicosis deaths. Western 
Europe, South Asia and East Asia had the highest number of 
asbestosis deaths, and East Asia, Australasia and Western Europe 
had the highest rate of asbestosis deaths (table 4—the rate data 
for individual pneumoconioses are not shown here).
Changes over time
For COPD, there was little change (4% rise) in the number of 
deaths due to occupational exposure to PMGF and SHS between 
1990 and 2016, but the (standardised) rate of death from COPD 
declined by 41% over this time. For asthmagens, the number of 
deaths due to occupational exposure increased by 7% and the 
rate of death declined by 36%. The number of deaths from pneu-
moconioses changed minimally (1%) over this period, but the 
rate of death from pneumoconioses declined by 41%. Changes 
in the numbers and rates of DALYs were similar to those seen for 
deaths, except for asthma, which had a 27% increase in DALYs 
between 1990 and 2016. The PAFs for asthma rose considerably 
over this time (21% for deaths; 28% for DALYs), but there was 
little change in the PAFs for COPD (table 5).
dIsCussIOn
This analysis of the GBD 2016 study has shown there is a consid-
erable burden of chronic respiratory disease worldwide and in all 
regions arising from exposure to occupational risk factors. Chronic 
obstructive pulmonary disease is the primary resulting disease, in 
terms of both deaths and DALYs, but asthma and pneumoconioses 
are also important. Rates were much higher in males than females 
for all these disorders, but important in both. The lower female rates 
reflect the fact that women are less likely to be employed in tasks 
that involve the relevant exposures.23 The results are consistent with 
those from the overall GBD respiratory analysis.30 The decreases in 
per capita burden for most measures, and the increase for asthma 
DALYs, result primarily from changes in the relevant PAFs that, in 
turn, reflect changes in the occupation and industry distribution, 
which are the basis of the exposure assessments.
PMGF, sHs and COPd
The global estimate of the PAF for COPD arising from occupational 
exposure to PMGF and SHS (17% for DALYs; 16% for deaths) 
is consistent with most published findings for individual coun-
tries and overall. These have typically reported PAFs of the order 
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Table 4 Global occupational- attributable deaths and DALYs from pneumoconioses due to exposure to pneumoconiotic dusts, by region, 2016 
(number and rate)*
region
deaths 
Asb*
deaths 
CWP*
deaths 
sil*
deaths 
Oth*
deaths 
total %
death 
rate† YLLs %‡ YLds‡ dALYs dALYs %
dALY 
rate†
High- income North America 674 283 118 78 1153 5.4 0.7 55.6 44.4 27 309 4.7 16.5
Australasia 87 1 11 6 105 0.5 0.8 88.4 11.6 1444 0.3 10.8
High- income Asia Pacific 345 279 486 477 1587 7.4 1.5 95.9 4.1 21 657 3.8 21.4
Western Europe 948 330 1388 147 2814 13.1 1.2 92.2 7.8 35 385 6.1 15.5
Southern Latin America 30 17 132 18 197 0.9 0.7 87.9 12.1 3236 0.6 12.5
Eastern Europe 37 29 35 172 272 1.3 0.3 56.5 43.5 8501 1.5 8.6
Central Europe 38 75 83 64 260 1.2 0.4 48.3 51.7 9058 1.6 16.0
Central Asia 14 3 2 49 68 0.3 0.3 63.9 36.1 2460 0.4 8.7
Central Latin America 38 33 90 75 235 1.1 0.3 49.5 50.5 9294 1.6 11.4
Andean Latin America 9 7 20 82 117 0.5 0.7 91.3 8.7 2351 0.4 12.6
Caribbean 4 2 5 13 24 0.1 0.1 61.9 38.1 739 0.1 4.4
Tropical Latin America 65 50 235 117 468 2.2 0.6 85.0 15.0 12 780 2.2 16.1
East Asia 345 960 6443 1080 8828 41.1 1.5 66.5 33.5 303 318 52.6 49.8
Southeast Asia 37 13 39 119 208 1.0 0.1 24.8 75.2 16 480 2.9 7.7
Oceania 5 1 7 17 30 0.1 1.4 86.0 14.0 816 0.1 29.6
North Africa and Middle East 69 43 93 195 401 1.9 0.3 62.7 37.3 13 882 2.4 8.2
South Asia 547 519 1089 1953 4109 19.1 0.9 90.8 9.2 92 603 16.0 18.4
Southern sub- Saharan Africa 133 12 51 64 260 1.2 1.3 92.6 7.4 6142 1.1 28.9
Western sub- Saharan Africa 10 3 5 38 57 0.3 0.1 74.8 25.2 2099 0.4 2.4
Eastern sub- Saharan Africa 47 19 55 108 229 1.1 0.4 89.6 10.4 5745 1.0 7.5
Central sub- Saharan Africa 12 6 15 33 66 0.3 0.4 90.0 10.0 1680 0.3 7.5
High SDI 2015 977 1855 770 5617 26.1 1.0 78.2 21.8 89 690 15.5 17.3
High- middle SDI 307 324 1702 569 2902 13.5 0.6 59.2 40.8 90 287 15.6 18.9
Middle SDI 598 778 5277 1521 8173 38.0 1.0 68.6 31.4 273 759 47.4 31.7
Low- middle SDI 485 548 1440 1781 4253 19.8 0.8 83.4 16.6 109 444 19.0 18.2
Low SDI 90 57 129 266 542 2.5 0.4 88.6 11.4 13 797 2.4 8.8
Global 3495 2685 10 402 4906 21 488 100.0 0.8 71.9 28.1 576 977 100.0 21.9
*YLL=years of life lost; YLD=years of life lived with disability; DALYs=disability- adjusted life years; PAF=population attributable fraction; Asb’=asbestosis; CWP=coal workers’ 
pneumoconiosis; ‘Sil’=silicosis; ‘Oth’=other pneumoconiosis.
†Per 100 000 persons.
‡Percentage of DALYs.
SDI, socio- demographic index.
of 10%–15%, although much higher values have been estimated, 
particularly for non- smokers, typically due to differences in the level 
or type of exposures of the included subjects or the use of different 
assumptions.1 10 31–35 In addition, as smoking rates diminish, the PAF 
for occupational risk factors will increase. In comparison, the GBD 
2016 study estimated PAFs for COPD in regard to smoking and 
SHS of 43% and ambient particulate matter pollution of 27%.22 
The CRA study (covering the year 2000) estimated 318 000 deaths 
and PAFs from occupational exposure of 13% based on DALYs and 
12% based on deaths.14 The Burden of Obstructive Lung Disease 
(BOLD) study documented a direct relationship between COPD 
prevalence and number of years worked in dusty jobs.36
Asthmagens and asthma
As with COPD related to occupational exposures, the occupational 
asthma PAF estimates of 10% for DALYs and 9% for deaths from 
this study are consistent with most published findings for indi-
vidual countries, which are of the order of 10%–15%3 7 8 10 28 and 
comparable to the PAF due to smoking (10% for DALYs; 14% for 
deaths).22 The CRA study, which was based on the year 2000, esti-
mated a PAF of 11% based on DALYs and 17% based on deaths 
(and estimated 38 000 deaths),14 the differences primarily arising 
from changes in the employment distribution and slight differences 
in the general methodology.22
Pneumoconiotic dusts and pneumoconioses
Obtaining reliable global information on pneumoconiosis cases is 
challenging. This analysis identified silicosis as the predominant 
pneumoconiosis, with much lower numbers of cases of asbestosis and 
CWP. The increase in rates with age is consistent with the published 
literature,37 and the number of deaths is consistent with the publicly 
available data for many countries, but also differs considerably 
for some others for which the estimates here are notably different 
from the numbers reported in the WHO Mortality Database.38 The 
reason for this is not clear, but presumably is because of the use of 
different primary data sources and assumptions in the GBD model-
ling process. It is likely that most of the moderate proportion of 
pneumoconiosis deaths and DALYs (both 23%) coded in GBD 2016 
as due to ‘Other pneumoconioses’ were actually due to silicosis, 
asbestosis or CWP, as these have always been identified as the three 
main pneumoconioses. The different coding is likely to have arisen 
due to incomplete coding in the source data and the way this was 
allocated to specific categories.
Methodological considerations and limitations
Most of the methodological issues specific to the three main 
outcomes of interest have already been considered in the relevant 
sections of the Discussion. The main general uncertainties have been 
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Table 5 Change in global occupational- attributable deaths and DALYs from chronic respiratory disease due to occupational exposure to 
asthmagens, PMGF, SHS and pneumoconiotic dusts between 1990 and 2016, number and per capita (number and percent [95% uncertainty 
interval])*
risk factor
deaths dALYs
1990† 2016 % change 1990 2016 % change
Asthmagens 35 228 37 574 6.7 1 845 494 2 339 480 26.8
(24 103–48 462) (28 362–47 936) (−19.5 to 36.1) (1 406 629–2 327 424) (1 860 896–2 923 319) (0.8 to 58.4)
PMGF+SHS 441 702 460 080 4.2 9 825 539 10 687 953 8.8
(367 000–521 000) (381 500–551 300) (−13.6 to 24.8) (8 149 400–11 533 600) (9 019 900–12 517 000) (−8.2 to 27.4)
Pneumoconiotic dusts 21 209 21 488 1.3 567 941 576 977 1.6
(16 000–31 400) (17 900–25 400) (−15.6 to 19.8) (442 576–832 555) (493 632–673 528) (−13.1 to 18.6)
Total 498 139 519 142 4.2 12 238 974 13 604 410 11.2
(407 000–600 900) (427 800–624 600) (−14.9 to 25.4) (10 667 700–13 881 800) (11 912 000–15 502,800) (−2.7 to 26.7)
 risk factor
deaths per 100 000 persons dALYs per 100 000 persons
1990† 2016 % change 1990 2016 % change
Asthmagens 2.2 1.4 −36.0 108 85 −21.4
(1.5–3.0) (1.0–1.8) (−51.7 to −18.1) (82–136) (67–106) (−37.5 to −1.7)
PMGF+SHS 31.0 18.2 −41.3 653 410 −37.1
(26.8–36.5) (15.0–21.9) (−51.7 to −29.4) (545–768) (346–482) (−47.1 to −26.1)
Pneumoconiotic dusts 1.43 0.84 −41.3 36 22 −39.7
(1.08–2.10) (0.70–0.99) (−51.0 to −30.8) (28–53) (19–26) (−48.5 to −29.7)
Total 34.6 20.4 −40.9 796 517 −35.1
(28.4–41.6) (16.7–24.6) (−51.6 to −28.8) (655–957) (431–613) (−45.8 to −23.0)
risk factor
Population attributable fraction (deaths) (%) Population attributable fraction (dALYs) (%)
1990* 2016 % change 1990 2016 % change
Asthmagens 7.4 (6.1–8.8) 8.9 (7.8–10.1) 20.6 (5.4–36.0) 7.7 (6.8–8.8) 9.9 (9.0–10.9) 27.6 (16.0–40.3)
PMGF+SHS 16.3 15.7 −3.6 16.4 16.9 2.5
(13.7–19.1) (13.8–18.6) (−20.0 to 14.0) (14.0–19.0) (14.3–19.7) (−13.0 to 19.8)
*DALYs=disability- adjusted Life Years; PMGF=particulate matter, gases and fumes; SHS=secondhand smoke.
†The numbers in brackets in the whole table are 95% uncertainty intervals.
considered in detail in the companion overview paper.21 Issues of 
particular relevance to the presented analysis included basing expo-
sure prevalence estimates on industry (for PMGF and SHS) and occu-
pation (for asthmagens); uncertainty in the prevalence and level of 
exposure to PMGF overall and in different industries; the potential 
for mismatch between the relative risk estimates used and the expo-
sure circumstances to which they have been applied; not explicitly 
taking into account the potential effect of differences in smoking 
habits and environmental exposures between regions and over time; 
probable heterogeneity in terms of how chronic respiratory condi-
tions are identified, diagnosed and managed worldwide; and not 
including some potentially relevant risk factors and outcomes such 
as respiratory infections,39 other occupational causes of fibrosis apart 
from pneumoconioses and lung disease arising from nanoparticle 
exposure.40 For both COPD and asthma, the extent and effect of 
any mismatch between the exposure and the relative risk estimate 
applied in LMI countries are not clear. It would be helpful to have 
usable information on this from LMI countries, which might allow 
different risk estimates to be applied in these countries if appropriate. 
However, currently the necessary data are not available.
Implications and uses of the data
The main finding of this study is that workplace exposures resulting 
in COPD, asthma and pneumoconioses remain important contrib-
utors to the burden of disease in all regions of the world. The rele-
vant exposures are respiratory and it should be possible to minimise 
all (or most), and in some instances to essentially eliminate them, 
through appropriate commitment to, and implementation of, 
exposure control interventions to decrease the airborne exposure 
levels of the relevant hazards. However, it must be recognised that 
there are a range of PMGF implicated as increasing the risk of 
COPD and hundreds of known occupational asthmagens. Elim-
ination or appropriate control of many of these exposures will 
take considerable resources and effort and requires continued 
vigilance. The study does not provide information on the cost 
or practicality of eliminating or better controlling the relevant 
exposures, and the results for COPD and pneumoconioses largely 
reflect past exposures. However, the high burden of COPD cases 
suggests the relevant exposures should be a priority in the area of 
occupational airborne exposures resulting in chronic respiratory 
disease. The findings also have implications for healthcare costs 
and social protection in older individuals. Finally, further invest-
ment in country- level data sources, especially in LMI countries, 
would help improve the accuracy and usefulness of the estimates 
generated by the GBD study.
Conclusions
There are many respiratory conditions that can arise directly, 
or indirectly, from work. The results from this study indi-
cate that non- malignant/non- infectious respiratory diseases 
arising from occupational exposures are an important cause 
of death and disability worldwide. Many of these cases 
should be preventable by adopting better health and safety 
approaches, particularly through improved engineering and 
working conditions.
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